Stenotrophomonas maltophilia – Clinical Significance, Treatment of Infections

Joanna Nowicka; Adriana Janczura; Martyna Lelonkiewicz

doi:10.2478/am-2023-0012

.blurhash-client-img { display: none !important; }

Stenotrophomonas maltophilia – Clinical Significance, Treatment of Infections

Advancements of Microbiology

Volume 62 (2023): Issue 3-4 (November 2023)

By: Joanna Nowicka, Adriana Janczura and Martyna Lelonkiewicz

Open Access

|Nov 2023

Abstract

Stenotrophomonas maltophilia is an important etiological factor of infections in patients with compromised immune systems, undergoing invasive diagnostic and therapeutic procedures, as well as in those suffering from cancer or cystic fibrosis. It poses a threat primarily to hospitalized patients. Due to its broad natural resistance and increasing acquired resistance, the therapy of infections caused by this pathogen is a challenge for modern medicine. The paper presents the current knowledge about the general characteristics, clinical significance and the most important pathogenicity factors of S. maltophilia. It also discusses therapeutic possibilities, including alternative ones, in infections caused by these microorganisms.

References

Araoka H., Yoneyama A.: Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 14, 355–363 (2012)
Search in Google Scholar Back to article
Avison M.B., Higgins C.S., von Heldreich C.J., Walsh T.R.: Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 45, 413–419 (2001)
Search in Google Scholar Back to article
Aydemir C., Aktas E., Eldes N., Kutsal E., Demirel F., Ege A.: Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis. Turk J Pediatr. 50, 89–90 (2008)
Search in Google Scholar Back to article
Bartoszek D., Fleischer M.: Znaczenie kliniczne Stenotrophomonas maltophilia. Forum zakażeń, 4, 165–171 (2013)
Search in Google Scholar Back to article
Belzer A., Weiss E., Etaee F., Bunick C.G., Damsky W., Nelson C.A.: Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics, 11, DOII:10.3390/antibiotics11101398 (2022)
Open DOI Search in Google Scholar Back to article
Bin Abdulhak A.A., Zimmerman V., Al Beirouti B.T., Baddour L.M., Tleyjeh I.M.: Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn Microbiol Infect Dis. 63, 330–333 (2009)
Search in Google Scholar Back to article
Bostanghadiri N., Ghalavand Z., Fallah F., Yadegar A., Ardebili A., Tarashi S., Pournajaf A., Mardaneh J., Shams S., Hashemi A.: Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran. Front Microbiol. 10, DOI:10.3389/fmicb.2019.01191 (2019)
Open DOI Search in Google Scholar Back to article
Brooke J.S.: Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 34, DOI:10.1128/CMR.00030-19 (2021)
Open DOI Search in Google Scholar Back to article
Brooke J.S.: Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol Rev. 25, 2–41 (2012)
Search in Google Scholar Back to article
Chang Y.T., Lin C.Y., Chen Y.H., Hsueh P.R.: Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 6, DOI:10.3389/fmicb.2015.00893 (2015)
Open DOI Search in Google Scholar Back to article
Chen S., Zou D.: Prognosis of hospital-acquired pneumonia/ventilator-associated pneumonia with Stenotrophomonas maltophiliaversus, Klebsiella pneumoniae in intensive care unit: A retrospectivecohort study. Clin Respir J. 16, 669–676 (2022)
Search in Google Scholar Back to article
Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 31 ed. Wayne, PA, 2021, https://clsi.org/media/z2uhcbmv/m100ed31_sample.pdf (14.03.2023)
Search in Google Scholar Back to article
Cowart MC, Ferguson CL.: Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Ther Drug Monit. 43, 146–149 (2021)
Search in Google Scholar Back to article
Duan Z., Qin J., Liu Y., Li C., Ying C.: Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital. BMC Microbiol. 20, DOI:10.1186/s12866-020-01985-3 (2020)
Open DOI Search in Google Scholar Back to article
Dzierżanowska D.: Antybiotykoterapia praktyczna. α-medica press, Bielsko-Biała, 2018
Search in Google Scholar Back to article
Farrell D.J., Sader H.S., Jones R.N.: Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 54, 2735–2737 (2010)
Search in Google Scholar Back to article
Fluit, A.C., Bayjanov, J.R., Aguilar, M.D., Cantón R., Elborn S., Tunney M.M., Scharringa J., Benaissa-Trouw B.J., Ekkelenkamp M.B.: Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections. BMC Microbiol. 22, DOI:10.1186/s12866-022-02466-5 (2022)
Open DOI Search in Google Scholar Back to article
Forrester J.B., Steed L.L, Santevecchi B.A., Flume P., Palmer-Long G.E., Bosso J.A.: In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infect Dis. 5, DOI:10.1093/ofid/ofy158 (2018)
Open DOI Search in Google Scholar Back to article
Gajdács M., Urbán E.: A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. Eur J Microbiol Immunol (Bp). 10, 91–97 (2020)
Search in Google Scholar Back to article
Gajdacs M., Urban E.: Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory track: a 10-year epidemiological snapshot. Health Serv Res Manag Epidemiol. 15, DOI:0.1177/2333392819870774 (2019)
Open DOI Search in Google Scholar Back to article
Gallagher T., Phan J., Oliver A., Chase A.B., England W.E., Wandro S., Hendrickson C., Riedel S.F., Whiteson K.: Cystic fibrosis-associates Stenotrophomonas maltophilia strain specific adaptations and responses to pH. J Bacteriol. 13, DOI:10.1128/JB.00478-18 (2019)
Open DOI Search in Google Scholar Back to article
Geller M., Nunes C.P., Oliviera L., Nigri R.: S. maltophilia pneumonia: a case report. Respir Med Case Rep. 24, 44–45 (2018)
Search in Google Scholar Back to article
Gibb J.; Wong D.W.: Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies. Antibiotics, 10, DOI:10.3390/antibiotics10101226 (2021)
Open DOI Search in Google Scholar Back to article
Gordon N.C., Wareham D.W.: Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 65, 483–489 (2010)
Search in Google Scholar Back to article
Granchelli A.M., Adler F.R., Keogh R.H., Kartsonaki C., Cox D.R., Liou T.G.: Microbial Interactions in the cystic fibrosis airway. J Clin Microbiol. 56, DOI: 10.1128/JCM.00354-18 (2018)
Open DOI Search in Google Scholar Back to article
Grillon A., Schramm F., Kleinberg M., Jehl F.: Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. PLoS One, 11, DOI:10.1371/journal.pone.0156690 (2016)
Open DOI Search in Google Scholar Back to article
Guerci P., Bougle A. i wsp. AZUREA research network.: Outcomes of Stenotrophomonas maltophilia hospital-aquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 23. DOI: 10.1186/s13054-019-2649-5 (2019)
Open DOI Search in Google Scholar Back to article
Healthcare-associated infections in intensive care units – Annual Epidemiological Report for 2017. European Centre for Disease Prevention and Control, 2019, https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1 (14.03.2023)
Search in Google Scholar Back to article
Huan Y., Kong Q., Mou H., Yi H.: Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front. Microbiol. 11, DOI:10.3389/fmicb.2020.582779 (2020)
Open DOI Search in Google Scholar Back to article
Huertas Méndez N.J., Vargas Casanova Y., Gómez Chimbi A.K., Hernández E., Leal Castro A.L., Melo Diaz J.M., Rivera Monroy Z.J., García Castañeda J.E.: Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076. Molecules, 22, DOI:10.3390/molecules22030452 (2017)
Open DOI Search in Google Scholar Back to article
IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0,3/31/2022 https://www.idsociety.org/news-publications-new/articles/2021/new-guidance-for-treating-antimicrobial-resistantinfections-released/ (14.03.2023)
Search in Google Scholar Back to article
Imoto W., Kakeya H. i wsp.: Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern Med. 59, 193–198 (2020)
Search in Google Scholar Back to article
Insuwanno W., Kiratisin P., Jitmuang A.: Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients. Infect. Drug. Resist. 13, 1559–1566 (2020)
Search in Google Scholar Back to article
Jacobson S., Junco Noa L., Wallace M.R., Bowman M.C.: Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 71, 3620–3622 (2016)
Search in Google Scholar Back to article
Jiang Z., Ren Y., Zhang C., Yin Y., Li C.: Community-Acquired Stenotrophomonas Maltophilia Infection in a Child: A Case Report and Literature Review. Infect Drug Resist. 15, 5469–5474 (2022)
Search in Google Scholar Back to article
Kalidasan V., Joseph N., Kumar S., Awang Hamat R., Neela V.K.: Iron and Virulence in Stenotrophomonas Maltophilia: All We Know So Far. Front. Cell. Infect. Microbiol. DOI:10.3389/fcimb.2018.00401 (2018)
Open DOI Search in Google Scholar Back to article
Kanchanasuwan S., Rongmuang J., Siripaitoon P.; Kositpantawong N., Charoenmak B., Hortiwakul T., Nwabor O.F., Chusri S.: Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia. J. Clin. Med. 11, DOI:10.3390/jcm11113085 (2022)
Open DOI Search in Google Scholar Back to article
Khan A., Pettaway C., Dien B.J., Arias C.A., Bhatti M.M., Humphries R.M.: Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 65, DOI:10.1128/AAC.02631-20 (2021)
Open DOI Search in Google Scholar Back to article
Kim E.J., Kim Y.C., Ahn J.Y., Jeong S.J., Ku N.S., Choi J.Y., Yeom J., Song Y.G.: Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteriemia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 19, DOI:10.1186/s12879-019-4394-4 (2019)
Open DOI Search in Google Scholar Back to article
Mahdi O., Eklund B., Fisher N.: Laboratory culture and maintenance of Stenotrophomonas maltophilia. Curr. Protoc. Microbiol. DOI:10.1002/9780471729259.mc06f01s32 (2014)
Open DOI Search in Google Scholar Back to article
Martinez-Servat S., Yero D., Huedo P., Marquez R., Molina G., Daura X., Gibert I.: Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing. Front. Microbiol. 9, DOI:10.3389/fmicb.2018.02871 (2018)
Open DOI Search in Google Scholar Back to article
Menetrey Q., Sorlin P., Jumas-Bilak E., Chiron R., Dupont C., Marchandin H. Achromobacter xylosoxidans and Stenotrophomonas maltophilia: emerging pathogens well-armed for life in the cystic fibrosis patients’ lung. Genes, 12, DOI:10.3390/genes12050610 (2021)
Open DOI Search in Google Scholar Back to article
Mojica M.F., Humphries R., Lipuma J.J., Mathers A.J., Rao G.G., Shelburne S.A., Fouts D.E., Van Duin D., Bonomo R.A.: Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob. Resist. DOI:10.1093/jacamr/dlac040 (2022)
Open DOI Search in Google Scholar Back to article
Mojica M.F., Rutter J.D., Taracila M., Abriata L.A., Fouts D.E., Papp-Wallace K.M., Walsh T.J., LiPuma J.J., Vila A.J., Bonomo R.A.: Population Structure, Molecular Epidemiology, and beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio, 10, DOI:10.1128/mBio.00405-19 (2019)
Open DOI Search in Google Scholar Back to article
Moriceau C., Eveillard M., Lemarié C., Chenouard R., Pailhoriès H., Kempf M.: Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone. Méd. Mal. Infect. 50, 305–307 (2020)
Search in Google Scholar Back to article
Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C.: In Vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI:10.1128/AAC.01699-19 (2020)
Open DOI Search in Google Scholar Back to article
Okazaki A., Avison M.B.: Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 51, 359–360 (2007)
Search in Google Scholar Back to article
Osawa K., Shigemura K., Kitagawa K., Tokimatsu I., Fujisawa M.: Risk factors for death from Stenotrophomonas maltophilia bacteriemia. J Infect Chemother. 24, 632–636 (2018)
Search in Google Scholar Back to article
Pompilio A., Di Bonaventura G. i wsp.: Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed – helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. BMC Microbiol. 12, DOI:10.1186/1471-2180-12-145 (2012)
Open DOI Search in Google Scholar Back to article
Rello J., Kalwaje E.V., Lagunes L., Alves J., Wunderink R.G., Conway-Morris A., Rojas J.N., Alp E., Zhang Z.: A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 38, 319–323 (2019)
Search in Google Scholar Back to article
Said M.S., Tirthani E., Lesho E.: Stenotrophomonas maltophilia. StatPearls, Treasure Island, Floryda, StatPearls, 2022
Search in Google Scholar Back to article
Simner P.J., Patel R.: Cefiderocol antimicrobial susceptibility testing considerations: The Achilles’ Heel of the Trojan Horse? J. Clin. Microbiol. 59, DOI:10.1128/JCM.00951-20 (2020)
Open DOI Search in Google Scholar Back to article
Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST, wersja 5.0, 15 grudnia 2021 https://korld.nil.gov.pl/wp-content/uploads/2022/03/Stanowisko-Zespolu-Roboczego-wersja-5_0-2021.pdf (14.03.2023)
Search in Google Scholar Back to article
Szewczyk M.E.: Diagnostyka bakteriologiczna. Wydawnictwo Naukowe PWN SA, Warszawa, 2019
Search in Google Scholar Back to article
The European Committee on Antimicrobial Susceptibility Testing – EUCAST, Guidance document on broth microdilution testing of cefiderocol, December 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf (14.03.2023)
Search in Google Scholar Back to article
The European Committee on Antimicrobial Susceptibility Testing „Clinical breakpoints – breakpoints and guidance”, January 1, 2022, https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (14.03.2023)
Search in Google Scholar Back to article
Trifonova A., Strateva T.: Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors, Infectious Diseases, 51, 168–178 (2019)
Search in Google Scholar Back to article
Trignano E., Manzo M.J., Fallico N., Maffei M., Marongiu F., Campus G.V., Rubino C.: First report of digital skin ulcer with Stenotrophomonas maltophilia infection in an immunocompetent patients. In Vivo, 28, 259–261 (2014)
Search in Google Scholar Back to article
Umar Z., Ashfaq S., Parikh A., Ilyas U., Foster A., Bhangal R., Khan J., Nassar M.: Stenotrophomonas maltophilia and urinary tract infections: a systematic review. Cureus. 14, DOI: 10.7759/cureus.26184 (2022)
Open DOI Search in Google Scholar Back to article
Walkty A., Adam H., Baxter M., Denisuik A., Lagacé-Wiens P., Karlowsky J.A., Hoban D.J., Zhanel G.G.: In Vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob. Agents Chemother. 58, 2554–2563 (2014)
Search in Google Scholar Back to article
Wang N., Tang C., Wang L.: Risk Factors for Acquired Stenotrophomonas maltophilia Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis. Front. Med. 8, DOI:10.3389/fmed.2021.808391 (2022)
Open DOI Search in Google Scholar Back to article
Wang Y.L., Scipione M.R., Dubrovskaya Y., Papadopoulos J.: Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 58, 176–182 (2014)
Search in Google Scholar Back to article
Zając O., Laudy A.E., Tyski S.: Biofilm, pompy MDR i inne mechanizmy oporności Stenotrophomonas maltophilia na związki przeciwdrobnoustrojowe. Post. Mikrobiol. 53, 264–276 (2014)
Search in Google Scholar Back to article
Zajac O.M., Tyski S., Laudy A.E.: Phenotypic and Molecular Characteristics of the MDR Efflux Pump Gene-Carrying Stenotrophomonas maltophilia Strains Isolated in Warsaw, Poland. Biology, 11, DOI:10.3390/biology11010105 (2022)
Open DOI Search in Google Scholar Back to article
Zhanel G.G., Karlowsky J.A. i wsp.: Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-_-lactamase inhibitor combinations. Drugs, 78, 65–98 (2018)
Search in Google Scholar Back to article
Zhu L., Ye X. i wsp.: Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteriemia: a retrospective study. BMC Infect Dis. 21, DOI:10.1186/s12879-021-06420-0 (2021)
Open DOI Search in Google Scholar Back to article
Zöllner S.K., Kampmeier S., Froböse N.J., Herbrüggen H., Masjosthusmann K., van den Heuvel A., Reicherts C., Ranft A., Groll A.H.: Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology. Front Oncol. 11, DOI:10.3389/fonc.2021.752037 (2021)
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/am-2023-0012 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252

Journal RSS Feed

Language: English, Polish

Page range: 133 - 143

Submitted on: Mar 1, 2022

Accepted on: Aug 1, 2023

Published on: Nov 9, 2023

Published by: Polish Society of Microbiologists

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

infekcje oportunistyczne,

MDR,

pacjenci z obniżoną odpornością,

S. maltophilia

Related subjects:

Life sciences,

Microbiology and virology

© 2023 Joanna Nowicka, Adriana Janczura, Martyna Lelonkiewicz, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 62 (2023): Issue 3-4 (November 2023)